Title of article
New drugs and targeted treatments in Hodgkin’s lymphoma
Author/Authors
Provencio، نويسنده , , Mariano and Sلnchez-Zapata، نويسنده , , Antonio and Sلnchez-Beato، نويسنده , , Margarita، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2014
Pages
8
From page
457
To page
464
Abstract
New drugs are being developed in recent years that may change the handling of relapsed and refractory Hodgkin’s lymphoma patients. Brentuximab vedotin treatment has already been approved by the FDA; and other drugs are promising, such as histone deacetylase inhibitors, bendamustine, lenalidomide and m-TOR inhibitors.
Keywords
lenalidomide , m-TOR inhibitors , Target treatments , Hodgkin’s lymphoma , Brentuximab vedotin , Deacetylase inhibitors , Bendamustine
Journal title
Cancer Treatment Reviews
Serial Year
2014
Journal title
Cancer Treatment Reviews
Record number
1836303
Link To Document